At-Risk Screened Children with Celiac Disease are Comparable in Disease Severity and Dietary Adherence to Those Found because of Clinical Suspicion: A Large Cohort Study - 18/04/17
Abstract |
Objective |
To assess whether children at risk for celiac disease should be screened systematically by comparing their baseline and follow-up characteristics to patients detected because of clinical suspicion.
Study design |
Five hundred four children with celiac disease were divided into screen-detected (n = 145) and clinically detected cohorts (n = 359). The groups were compared for clinical, serologic, and histologic characteristics and laboratory values. Follow-up data regarding adherence and response to gluten-free diet were compared. Subgroup analyses were made between asymptomatic and symptomatic screen-detected patients.
Results |
Of screen-detected patients, 51.8% had symptoms at diagnosis, although these were milder than in clinically detected children (P < .001). Anemia (7.1% vs 22.9%, P < .001) and poor growth (15.7% vs 36.9%, P < .001) were more common, and hemoglobin (126 g/l vs 124 g/l, P = .008) and albumin (41.0 g/l vs 38.0 g/l, P = .016) were lower in clinically detected patients. There were no differences in serology or histology between the groups. Screen-detected children had better dietary adherence (91.2% vs 83.2%, P = .047). The groups showed equal clinical response (97.5% vs 96.2%, P = .766) to the gluten-free diet. In subgroup analysis among screen-detected children, asymptomatic patients were older than symptomatic (9.0 vs 5.8 years of age, P = .007), but the groups were comparable in other variables.
Conclusions |
More than one-half of the screen-detected patients with celiac disease had symptoms unrecognized at diagnosis. The severity of histologic damage, antibody levels, dietary adherence, and response to treatment in screen-detected cases is comparable with those detected on a clinical basis. The results support active screening for celiac disease among at-risk children.
Le texte complet de cet article est disponible en PDF.Keywords : clinical presentation, screening, symptoms, villous atrophy, celiac antibodies, follow-up, gluten-free diet
Abbreviations : EmA, Rf, T1DM, TG2ab
Plan
Supported by The Academy of Finland Research Council for Health, the Competitive State Research Financing of the Expert Responsibility Areas of Tampere University Hospital, the Sigrid Juselius Foundation, the Mary and Georg Ehrnrooth Foundation, the Foundation for Pediatric Research, the Finnish Medical Foundation and the Finnish Celiac Society. The authors declare no conflicts of interest. |
|
Portions of the study were presented at the 16th International Celiac Disease Symposium, Prague, Czech Republic, June 21-24, 2015; and as a poster at the annual meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, Athens, Greece, May 25-28, 2016. |
Vol 183
P. 115 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?